[Artificial contrasting during magnetic resonance tomography].
Sergeev
P V
PV
Moscow State Medical University.
Panov
O V
OV
Egorova
S V
SV
Bolotova
E N
EN
Shimanovskii
N L
NL
Akhadov
T A
TA
Sviridov
N K
NK
D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D004333:Drug Administration Routes; D005682:Gadolinium / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D019786:Gadolinium DTPA; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008536:Meglumine / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D004369:Pentetic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000737:chemistry; D012449:Safety
D003287:Contrast Media; D006571:Heterocyclic Compounds; D009942:Organometallic Compounds; C062402:gadoteridol; D008536:Meglumine; D004369:Pentetic Acid; C064925:gadodiamide; D005682:Gadolinium; D019786:Gadolinium DTPA; C072417:gadoterate meglumine